Iterum Therapeutics (NASDAQ:ITRM) posted its quarterly earnings results on Wednesday. The company reported ($1.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.50) by ($0.43), Fidelity Earnings reports. Iterum Therapeutics had a negative net margin of 11,956.64% and a negative return on equity of 83.95%.
NASDAQ ITRM traded down $0.01 during trading hours on Thursday, hitting $6.79. The company had a trading volume of 11,986 shares, compared to its average volume of 7,086. Iterum Therapeutics has a fifty-two week low of $4.70 and a fifty-two week high of $11.22. The company has a current ratio of 4.36, a quick ratio of 4.36 and a debt-to-equity ratio of 0.24. The business has a fifty day moving average of $6.63. The company has a market cap of $96.60 million, a price-to-earnings ratio of -0.96 and a beta of 2.05.
Several research firms recently issued reports on ITRM. Zacks Investment Research raised Iterum Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 17th. Royal Bank of Canada dropped their price target on Iterum Therapeutics to $17.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 15th. Finally, HC Wainwright reissued a “buy” rating and set a $17.00 price target on shares of Iterum Therapeutics in a research report on Thursday. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Iterum Therapeutics has a consensus rating of “Buy” and an average target price of $15.75.
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
Featured Story: Price-Sales Ratio
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.